The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

A recent study has uncovered an unexpected connection between our diets and the progression of lung cancer, specifically a ...

Cells expressing the basal cell marker KRT5 have been fluorescently labelled and can be seen spreading throughout the bronchial tree The ‘cell of origin’ of the second most common lung cancer and the ...

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish ...

Dr. Chao H. Huang explains his skepticism regarding a recent study that linked chronic pain to significantly higher lung ...

The five-year survival rate for lung cancer is around 56% when it is detected while the cancer is still localized. But few cancers are caught at this early stage. To improve survival rates and ...

will be available for those with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC), where tumours have specific protein and genetic markers. It is the first drug to ...

cervical and lung cancers, researchers said. Blood testing offers an opportunity to detect dozens of different cancer types ...